{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:44:51Z","timestamp":1788443091804,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,6]]},"DOI":"10.7759\/cureus.32264","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T19:26:50Z","timestamp":1670354810000},"source":"Crossref","is-referenced-by-count":2,"title":["Erythema Dyschromicum Perstans After Adalimumab Treatment"],"prefix":"10.7759","author":[{"given":"Ghazal  G","family":"Alsisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed H","family":"Alsisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alauldin K","family":"Alhowaish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wardah S","family":"Alshammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2001.00832.x","article-title":"Psoriasis - epidemiology and clinical spectrum","volume":"26","author":"Christophers E","year":"2001","unstructured":"Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol. 2001, 26:314-20. 10.1046\/j.1365-2230.2001.00832.x","journal-title":"Clin Exp Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon A","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019, 20:1475. 10.3390\/ijms20061475","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032276","article-title":"Psoriasis treatment: current and emerging directed therapies","volume":"64","author":"Winterfield LS","year":"2005","unstructured":"Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis. 2005, 64:87-90. 10.1136\/ard.2004.032276","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12251","article-title":"New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors","volume":"28","author":"Gaspari AA","year":"2015","unstructured":"Gaspari AA, Tyring S. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. Dermatol Ther. 2015, 28:179-93. 10.1111\/dth.12251","journal-title":"Dermatol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07682.x","article-title":"Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists","volume":"156","author":"Lee HH","year":"2007","unstructured":"Lee HH, Song IH, Friedrich M, et al.. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007, 156:486-91. 10.1111\/j.1365-2133.2007.07682.x","journal-title":"Br J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2008.03625.x","article-title":"Ashy dermatoses - a critical review of the literature and a proposed simplified clinical classification","volume":"47","author":"Zaynoun S","year":"2008","unstructured":"Zaynoun S, Rubeiz N, Kibbi AG. Ashy dermatoses - a critical review of the literature and a proposed simplified clinical classification. Int J Dermatol. 2008, 47:542-4. 10.1111\/j.1365-4632.2008.03625.x","journal-title":"Int J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5114\/dr.2014.41068","article-title":"Erythema dyschromicum perstans (ashy dermatosis) during the treatment with infliximab in a child with crohn disease","volume":"1","author":"Sobjanek M","year":"2014","unstructured":"Sobjanek M, Lange M, Michaj\u0142owski I, et al.. Erythema dyschromicum perstans (ashy dermatosis) during the treatment with infliximab in a child with crohn disease. Dermatology Review. 2014, 1:27-34. 10.5114\/dr.2014.41068","journal-title":"Dermatology Review"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.08.062","article-title":"HLA-DR association with the genetic susceptibility to develop ashy dermatosis in Mexican Mestizo patients","volume":"56","author":"Correa MC","year":"2007","unstructured":"Correa MC, Memije EV, Vargas-Alarc\u00f3n G, et al.. HLA-DR association with the genetic susceptibility to develop ashy dermatosis in Mexican Mestizo patients. J Am Acad Dermatol. 2007, 56:617-20. 10.1016\/j.jaad.2006.08.062","journal-title":"J Am Acad Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1988.01670070015007","article-title":"Erythema dyschromicum perstans following human immunodeficiency virus seroconversion in a child with hemophilia B","volume":"124","author":"Venencie PY","year":"1988","unstructured":"Venencie PY, Lemay D, Verroust F. Erythema dyschromicum perstans following human immunodeficiency virus seroconversion in a child with hemophilia B. Arch Dermatol. 1988, 124:1013. 10.1001\/archderm.1988.01670070015007","journal-title":"Arch Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2001.01196-2.x","article-title":"Erythema dyschromicum perstans and hepatitis C virus infection","volume":"40","author":"Kontochristopoulos GJ","year":"2001","unstructured":"Kontochristopoulos GJ, Aroni K, Anagnostopoulos G, Nakopoulou L, Tassopoulos NC. Erythema dyschromicum perstans and hepatitis C virus infection. Int J Dermatol. 2001, 40:346-8. 10.1046\/j.1365-4362.2001.01196-2.x","journal-title":"Int J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000251444","article-title":"Ingestion of ammonium nitrate as a possible cause of erythema dyschromicum perstans (ashy dermatosis)","volume":"150","author":"Jablonska S","year":"1975","unstructured":"Jablonska S. Ingestion of ammonium nitrate as a possible cause of erythema dyschromicum perstans (ashy dermatosis). Dermatologica. 1975, 150:287-91. 10.1159\/000251444","journal-title":"Dermatologica"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2018.08.003","article-title":"Erythema dyschromicum perstans: a case report and systematic review of histologic presentation and treatment","volume":"4","author":"Leung N","year":"2018","unstructured":"Leung N, Oliveira M, Selim MA, McKinley-Grant L, Lesesky E. Erythema dyschromicum perstans: a case report and systematic review of histologic presentation and treatment. Int J Womens Dermatol. 2018, 4:216-22. 10.1016\/j.ijwd.2018.08.003","journal-title":"Int J Womens Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.41393","article-title":"Ashy dermatosis-like pigmentation due to ethambutol","volume":"74","author":"Srivastava N","year":"2008","unstructured":"Srivastava N, Solanki LS, Chand S, Garbyal RS, Singh S. Ashy dermatosis-like pigmentation due to ethambutol. Indian J Dermatol Venereol Leprol. 2008, 74:281-2. 10.4103\/0378-6323.41393","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1996.tb02360.x","article-title":"Chlorothalonil, a possible cause of erythema dyschromicum perstans (ashy dermatitis)","volume":"35","author":"Penagos H","year":"1996","unstructured":"Penagos H, Jimenez V, Fallas V, O'Malley M, Maibach HI. Chlorothalonil, a possible cause of erythema dyschromicum perstans (ashy dermatitis). Contact Dermatitis. 1996, 35:214-8. 10.1111\/j.1600-0536.1996.tb02360.x","journal-title":"Contact Dermatitis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01484.x","article-title":"Cutaneous hyperpigmentation induced by omeprazole mimicking ashy dermatosis","volume":"20","author":"Ram\u00edrez-Hern\u00e1ndez M","year":"2006","unstructured":"Ram\u00edrez-Hern\u00e1ndez M, Mart\u00ednez-Escribano JA, Mart\u00ednez-Barba E, Alcolea-Rubio LA, Ibarra-Berrocal IJ. Cutaneous hyperpigmentation induced by omeprazole mimicking ashy dermatosis. J Eur Acad Dermatol Venereol. 2006, 20:584-7. 10.1111\/j.1468-3083.2006.01484.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nri1184","article-title":"Signalling pathways of the TNF superfamily: a double-edged sword","volume":"3","author":"Aggarwal BB","year":"2003","unstructured":"Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003, 3:745-56. 10.1038\/nri1184","journal-title":"Nat Rev Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.491530","article-title":"Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor \u03b1-associated diseases from a molecular view","volume":"288","author":"Hu S","year":"2013","unstructured":"Hu S, Liang S, Guo H, et al.. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor \u03b1-associated diseases from a molecular view. J Biol Chem. 2013, 288:27059-67. 10.1074\/jbc.M113.491530","journal-title":"J Biol Chem"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.768530","article-title":"Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis","volume":"16","author":"Kirson NY","year":"2013","unstructured":"Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi M. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis. J Med Econ. 2013, 16:479-89. 10.3111\/13696998.2013.768530","journal-title":"J Med Econ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0697","article-title":"Hyperpigmentation of the face following adalimumab treatment","volume":"89","author":"Blomberg M","year":"2009","unstructured":"Blomberg M, Zachariae CO, Gr\u00f8nh\u00f8j F. Hyperpigmentation of the face following adalimumab treatment. Acta Derm Venereol. 2009, 89:546-7. 10.2340\/00015555-0697","journal-title":"Acta Derm Venereol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.87a.19119","article-title":"Cutaneous adverse effects of biologic medications","volume":"87","author":"Pasadyn SR","year":"2020","unstructured":"Pasadyn SR, Knabel D, Fernandez AP, Warren CB. Cutaneous adverse effects of biologic medications. Cleve Clin J Med. 2020, 87:288-99. 10.3949\/ccjm.87a.19119","journal-title":"Cleve Clin J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/128028-erythema-dyschromicum-perstans-after-adalimumab-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:44:17Z","timestamp":1707507857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/128028-erythema-dyschromicum-perstans-after-adalimumab-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.32264","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,6]]}}}